On Friday, the FDA approved Apellis Pharmaceuticals' Syfovre (pegcetacoplan) as the first treatment for geographic atrophy (GA), a leading cause of blindness.
GA causes areas of the retinal cells to waste away and die in some patients with age-related macular degeneration. The condition affects over five million worldwide and, until now, progressed relentlessly without any treatments to slow the decline in patient’s vision.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,